HomeInsightsStock Comparison

Cipla Ltd vs Strides Pharma Science Ltd Stock Comparison

Cipla Ltd vs Strides Pharma Science Ltd Stock Comparison

Last Updated on: May 10, 2025

Key Highlights

  • The Latest Trading Price of Cipla Ltd is ₹ 1478 as of 09 May 15:30.
  • The P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 29.3 on March 2024 . This represents a CAGR of 5.90% over 5 yearsThe P/E Ratio of Strides Pharma Science Ltd changed from 79.4 on March 2020 to 0 on March 2024 . This represents a CAGR of -100.00% over 5 years.
  • The Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 120673 crore on March 2024 . This represents a CAGR of 28.75% over 5 yearsThe Market Cap of Strides Pharma Science Ltd changed from ₹ 2888 crore on March 2020 to ₹ 7192 crore on March 2024 . This represents a CAGR of 20.01% over 5 years.
  • The revenue of Cipla Ltd for the Dec '24 is ₹ 7294 crore as compare to the Sep '24 revenue of ₹ 7241 crore. This represent the growth of 0.73% The revenue of Strides Pharma Science Ltd for the Dec '24 is ₹ 1160 crore as compare to the Sep '24 revenue of ₹ 1195 crore. This represent the decline of -2.94%.
  • The ebitda of Cipla Ltd for the Dec '24 is ₹ 2210 crore as compare to the Sep '24 ebitda of ₹ 2076 crore. This represent the growth of 6.47% The ebitda of Strides Pharma Science Ltd for the Dec '24 is ₹ 214.45 crore as compare to the Sep '24 ebitda of ₹ 208.49 crore. This represent the growth of 2.86%.
  • The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1583 crore over 7 quarters. This represents a CAGR of 30.30% The net profit of Strides Pharma Science Ltd changed from ₹ -9.36 crore to ₹ 90.04 crore over 7 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.74 % on March 2024 . This represents a CAGR of 12.57% over 5 yearsThe Dividend Payout of Strides Pharma Science Ltd changed from 104.26 % on March 2020 to 35.08 % on March 2024 . This represents a CAGR of -19.58% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cipla Ltd

  • Cipla Limited is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Strides Pharma Science Ltd

  • Strides Pharma Science Limited is a global pharmaceutical company headquartered in Bengaluru, India.
  • The Company mainly operates in the regulated markets including key markets of US, Europe, Australia, South Africa.
  • It has presence in the emerging markets largely in Africa where it has a branded business and is a pre qualified supplier to donor-funded programme though their institutional business. The Company is an integrated manufacturer and exporter of Finished Pharmaceutical Dosage forms for both branded and generic.
  • It manufactures a very wide spectrum of ethical pharmaceutical products, OTC products and nutraceuticals.
  • Their dosage forms range includes tablets, capsules, soft gelatin capsules, parenterals and semisolids.

Cipla Ltd News Hub

News

Cipla's Goa API facility receives VAI status from USFDA

According to an exchange filing dated 20 January 2025, the USFDA conducted an inspection o...

Read more

21 Apr 2025 11:32

News

Cipla allots 23,282 equity shares under ESOS

Cipla has allotted 23,282 fully paid-up equity shares of Rs 2 each, pursuant to exercise o...

Read more

17 Apr 2025 16:12

News

Cipla receives USFDA approval for Protein-bound Paclitaxel for Injectable Suspension

Cipla has received final approval from the United States Food and Drug Administration (USF...

Read more

11 Apr 2025 09:27

News

Cipla jumps on receiving approval from USFDA for protein-bound Paclitaxel

Cipla's formulation is an AB-rated therapeutic equivalent of Abraxane and is indicated for...

Read more

11 Apr 2025 10:12

News

Cipla to table results

Cipla will hold a meeting of the Board of Directors of the Company on 13 May 2025. Powered...

Read more

08 Apr 2025 09:40

News

USFDA classifies cGMP inspection of Cipla's Virgonagar facility as VAI

Cipla has classified its current Good Manufacturing Practices (cGMP) inspection of the com...

Read more

08 Feb 2025 11:16

Strides Pharma Science Ltd News Hub

News

Strides Pharma's US arm acquires four drugs to bolster portfolio

The portfolio consists of liquids and immediate release solid orals which are in the thera...

Read more

30 Apr 2025 07:51

News

Strides Pharma Science announces incorporation of step-down subsidiary

Arco Lab, a wholly owned subsidiary of Strides Pharma Science has incorporated a new wholl...

Read more

11 Apr 2025 15:34

News

Strides Pharma Science announces acquisition of Singapore-based Amexel

Strides Pharma Global (SPG), a step-down wholly-owned subsidiary of Strides Pharma Science...

Read more

15 Mar 2025 15:45

News

Strides Pharma Science appoints director

Strides Pharma Science has appointed Mukta Arora (DIN: 07225715) as Independent Director o...

Read more

31 Jan 2025 10:49

News

Strides Pharma Science announces change in directorate

Strides Pharma Science announced the change in designation of Arun Kumar (DIN: 00084845) f...

Read more

31 Jan 2025 10:50

News

Strides Pharma Science to hold board meeting

Strides Pharma Science will hold a meeting of the Board of Directors of the Company on 30 ...

Read more

25 Jan 2025 09:49

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Strides Pharma Science Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Strides Pharma Science Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cipla Ltd and Strides Pharma Science Ltd

Which company has a larger market capitalization, Cipla Ltd or Strides Pharma Science Ltd?

Market cap of Cipla Ltd is 119,409 Cr while Market cap of Strides Pharma Science Ltd is 5,879 Cr

What are the key factors driving the stock performance of Cipla Ltd and Strides Pharma Science Ltd?

The stock performance of Cipla Ltd and Strides Pharma Science Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Strides Pharma Science Ltd?

As of May 10, 2025, the Cipla Ltd stock price is INR ₹1478.5. On the other hand, Strides Pharma Science Ltd stock price is INR ₹638.0.

How do dividend payouts of Cipla Ltd and Strides Pharma Science Ltd compare?

To compare the dividend payouts of Cipla Ltd and Strides Pharma Science Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions